This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Mumps is a viral infection first described by Hippocrates that in its classical form causes acute parotitis and, less frequently, orchitis, meningitis and pneumonia.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
In 2021, 1 567 cases of mumps were reported to ECDC by 27 European Union/European Economic Area(EU/EEA) Member States, with an overall notification rate of 0.4 cases per 100 000 population. This wassignificantly lower than the notification rates reported during the previous four years (range 1.7-4.2).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis B. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis B.